Autoimmune Diseases Treatment Market By Type (Chemical-based Drugs, Biological Drugs) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

This report on global autoimmune diseases treatment market studies various drugs used for treatment of autoimmune diseases along with pipeline analysis of upcoming potential drugs. Autoimmune diseases (ADs) are a family of more than 80 chronic, and often disabling, illnesses broadly characterized by immune system dysfunction leading to the loss of tolerance to self-antigens, presence of increased level of autoantibodies, inflammatory and mediatory cells and resulting chronic inflammation. Thus, drug pipeline of autoimmune diseases treatment market comprises potential drugs which are more target-specific and possess innovative properties. 

For the purpose of this study, the various therapeutic types studied include chemical-based drugs and biological drugs; further, chemical-based are segmented as immunosuppressant drugs, NSAIDs, and corticosteroids. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for autoimmune diseases treatment market comprises projected market sales of Phase III drugs estimated till 2022. There are more than 80 types of clinically different autoimmune diseases. Some of the common types of autoimmune diseases are Hashimoto's thyroiditis, type I diabetes, Crohn's disease, multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis systemic lupus erythematosus, and psoriasis. We have estimated sales of very specific molecules based on the type (chemical-based or biological), disease prevalence, sponsor, depicted peak sales by leading market experts and other factors.

The geographic segmentation of the global autoimmune diseases treatment market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

For the purpose of this study, the global autoimmune diseases treatment market is categorized into:

• North America
• Europe
• Asia Pacific
• Rest of the World
•  

North America was observed as the largest market for autoimmune diseases treatment in the base year 2015 due to growing prevalence of several forms of autoimmune disorders, and presence of government initiatives such as Affordable Care Act and Patient Protection Act. According to the American Autoimmune Related Diseases Association (AARDA), autoimmune disease is one of the top 10 leading causes of death in female children and women in all age groups up to 64 years of age and AARDA also estimates that around 50 million Americans suffer from autoimmune disease. 

Europe is expected to be the second largest market due to rising healthcare infrastructure and penetration of new technologies. Dominance of North America and Europe in autoimmune disease market is attributed by factors like rising prevalence of autoimmune diseases, increasing investments in R&D and higher disposable income in these regions. However, factors such as developing health infrastructure, increasing awareness among people about heath care and aging population are going to fuel the rapid growth of autoimmune disease treatment market in Asia-Pacific region in the near future.